A study of IgPro20 to prevent infections in myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels and are being treated with a bispecific antibody. If you have relapsed or refractory myeloma and have recently started a bispecific antibody, this study might help protect you from getting serious infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or refractory multiple myeloma and are taking a bispecific antibody
- You have received between 1 and 4 cycles of this antibody treatment
- You are 18 years old or older
- You have an ECOG performance status of 3 or less, meaning you are up and about for at least half the day
- You are expected to live longer than 12 months
- You do not have any serious infections in the last 3 months, no active hepatitis or HIV, and no history of allergic reactions to IgG products
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
This study tests if adding Gammagard (a type of antibody therapy) to your multiple myeloma treatment with Tecvayli can help prevent serious infections. You may qualify if you recently started Tecvayli and are still responding to it.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
This study tests CM336, a new type of immunotherapy drug, for patients with multiple myeloma (a blood cancer) that has come back or progressed after their first treatment. The trial aims to see if this drug can help control the disease in patients at high risk of relapse.
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.